In contrast, the MTHFR A1298C polymorphism may be associated with a decreased risk of adverse reactions (although no statistical significance was observed), which is generally consistent with the findings of a systematic evaluation in patients with hematological malignancies. This evidence concerns the gene MTHFR and hematologic disorder.